Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 3:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Stem cell mobilization Clear all
Completed Phase 2 Interventional Results available

AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts

NCT00396331
View directory record Official record
Conditions
Autologous Stem Cell Transplantation
Interventions
G-CSF plus plerixafor
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 78 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
8
States / cities
Duarte, California • Tampa, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Sep 17, 2026, 3:06 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

NCT04653246
View directory record Official record
Conditions
Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Autologous Stem Cell Transplant
Interventions
Isatuximab, Lenalidomide, Bortezomib Injection, Dexamethasone
Drug
Lead sponsor
Jacob Laubach, MD
Other
Eligibility
75 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 17, 2026, 3:06 AM EDT
Recruiting Not applicable Interventional

Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection

NCT01189786
View directory record Official record
Conditions
Stem Cell Transplant, Allogeneic
Interventions
CliniMACS CD34 Reagent system
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 70 Years
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 17, 2026, 3:06 AM EDT
Terminated Phase 2 Interventional Results available

CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

NCT01746173
View directory record Official record
Conditions
T-cell Non-Hodgkin Lymphoma
Interventions
Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, Prednisone, Filgrastim, Plerixafor, Stem Cell Collection, Palifermin, Gemcitabine, Busulfan, Melphalan, Stem Cell Transplant
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2023 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers

NCT00082329
View directory record Official record
Conditions
Healthy
Interventions
AMD 3100 (Mozobil plerixafor), Granulocyte colony-stimulating factor (G-CSF)
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Phase 1 Interventional

HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies

NCT00001748
View directory record Official record
Conditions
Graft vs Host Disease, Hematologic Neoplasms, Lymphoma, Myelodysplastic Syndromes, Myeloid Leukemia
Interventions
Peripheral blood progenitor cell transplant
Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 17, 2026, 3:06 AM EDT
Completed No phase listed Observational

Observational Study to Evaluate Hematopoietic Progenitor Cell Mobilization in Patients With Newly Diagnosed Multiple Myeloma

NCT03200626
View directory record Official record
Conditions
Multiple Myeloma, Bone Marrow Transplant Complications
Interventions
Autologous hematopoietic cell transplant
Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 70 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Not applicable Interventional

Proteomics and Stem Cell Therapy as a New Vascularization Strategy

NCT02802852
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Pneumatic calf compression, Filgrastim
Device · Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
35 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 14, 2021 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Phase 2 Interventional Results available

MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma

NCT04552743
View directory record Official record
Conditions
Multiple Myeloma
Interventions
MGTA-145, Plerixafor
Drug
Lead sponsor
Surbhi Sidana, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2022 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Phase 1 Interventional

Stem Cell (Modified Bone Marrow) Transplantation in HIV-Infected Patients With Blood Cancer

NCT00005785
View directory record Official record
Conditions
Hematologic Neoplasm, HIV Infection
Interventions
GCSF Mobilized Allogeneic PBSC Cultured w/Cytokines; Transduced w/RV
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 17, 2026, 3:06 AM EDT
Completed No phase listed Observational

Effects of Mobility Dose on Discharge Disposition in Critically Ill Stroke Patients

NCT03347656
View directory record Official record
Conditions
Sarcopenia, Stroke, Acute, Muscle Weakness, Critical Illness
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
164 participants
Timeline
2017 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Sep 17, 2026, 3:06 AM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

A Dosing Study of Hyperbaric Oxygen Therapy (HBOT) on Epigenetic Aging

NCT05297019
View directory record Official record
Conditions
Aging
Interventions
Hyperbaric Oxygen Therapy
Procedure
Lead sponsor
TruDiagnostic
Industry
Eligibility
40 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Florham Park, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Not applicable Interventional Results available

Haploidentical CD34+ Selected Cells Combined With Single Unit Umbilical Cord Blood Transplant for Treatment of High-risk Hematologic Disorders

NCT03093844
View directory record Official record
Conditions
Hematologic Disorders
Interventions
Miltenyi CliniMACS® CD34 Reagent System
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Phase 1 Interventional

Granulocyte Colony-stimulating Factor (G-CSF) Plus or Minus AMD3100 for Engraftment Post Allogeneic Transplant

NCT01026987
View directory record Official record
Conditions
Stem Cell Transplant Patients
Interventions
G-CSF, AMD3100, Leukapheresis, Stem Cell Infusion
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Phase 2 Interventional Results available

Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients

NCT00322387
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Multiple Myeloma
Interventions
G-CSF and plerixafor
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
5
States / cities
Duarte, California • Beech Grove, Indiana • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma

NCT02441686
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib, Lenalidomide, Dexamethasone, Stem Cell Mobilization, Autologous Stem Cell Transplant
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
8
States / cities
Denver, Colorado • Brewer, Maine • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Phase 2 Interventional

The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers

NCT00001873
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Graft vs Host Disease, Hematologic Neoplasm, Multiple Myeloma, Myelodysplastic Syndrome
Interventions
Isolex 300i plus MoAbs
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
10 Years to 55 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Phase 1 Interventional Results available

Safety Trial of NK DLI From 6/6 HLA Matched Family Member Following Nonmyeloablative ASCT

NCT00586690
View directory record Official record
Conditions
Lymphoma
Interventions
NK Cell infusion using CD56 monoclonal antibody, Donor Apheresis
Device · Procedure
Lead sponsor
David Rizzieri, MD
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Phase 3 Interventional Results available

Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase I

NCT01004406
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
intensive LDL-lowering therapy, standard statin monotherapy
Device · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
31 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Phase 2 Interventional Results available

Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL

NCT00490529
View directory record Official record
Conditions
Lymphoma, Mantle-Cell
Interventions
CpG-MCL vaccine, PF-3512676, Vaccine-primed T-cells, Autologous hematopoietic stem cell transplant (HSCT), Rituximab, Standard induction chemotherapy, Cyclophosphamide, Filgrastim
Biological · Procedure · Drug
Lead sponsor
Ronald Levy
Other
Eligibility
21 Years to 70 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Not applicable Interventional Results available

Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies

NCT00741455
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Stem Cell Transplant, G-CSF, Fludarabine, cyclophosphamide, Cyclosporine, Methotrexate
Procedure · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2020
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Sep 17, 2026, 3:06 AM EDT
Withdrawn Phase 1 Interventional

Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas

NCT03920631
View directory record Official record
Conditions
B Cell Lymphomas
Interventions
Nivolumab, Microtransplantation
Drug · Biological
Lead sponsor
Ahmed Galal, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Phase 2 Interventional

Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer

NCT00003553
View directory record Official record
Conditions
Kidney Cancer
Interventions
HLA Matched Peripheral BLood Stem Cells
Other
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Sep 17, 2026, 3:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Stem Cell Gene Therapy for Cystinosis

NCT03897361
View directory record Official record
Conditions
Lysosomal Storage Diseases, Cystinosis
Interventions
CTNS-RD-04 (including CTNS-RD-04-LB manufactured with LentiBOOST)
Genetic
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 17, 2026, 3:06 AM EDT